Literature DB >> 30935177

Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.

K S Mehta1, S D Sinha2, Bandi Vamsi3, Bala Reddy4, N R Naidu5, P A Thakur5, Chary Sreenivasa5, V P R Reddy6, R Pandey7, S Durugkar8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30935177

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN： 0004-5772


× No keyword cloud information.
  2 in total

1.  Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India.

Authors:  Rufaida Mazahir; Kanav Anand; P K Pruthi
Journal:  Eur J Pediatr       Date:  2022-10-11       Impact factor: 3.860

2.  Safety, Tolerability, and Immunogenicity of Prescribed Usage of Darbepoetin-Alfa (Hetero Biopharma) in Patients of Chronic Kidney Disease With Renal Anemia: A Post-Marketing Surveillance Study.

Authors:  Shubhadeep D Sinha; Vamsi K Bandi; Bala B Reddy; Pankaj Thakur; Sreenivasa Chary; Leela Talluri; Sheejith Kakkunnath
Journal:  Cureus       Date:  2021-04-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.